Isatuximab in combination with cemiplimab in patients with relapsed/refractory multiple myeloma: A phase 1/2 study.

Alexander M LesokhinRichard LeBlancMeletios A DimopoulosMarcelo CapraCarmelo Carlo-StellaLionel KarlinJean-Francois CastillouxPeter ForsbergGurdeep ParmarAxel TosikyanLudek PourVincent RibragRossella RibollaAl-Ola AbdallahNadia Le RouxLiyan DongHelgi van de VeldeLaurent MayrargueLucie LépineSandrine MacéPhillipe Moreau

Published in: Cancer medicine (2023)

Our results suggest a marginal benefit by adding cemiplimab to isatuximab, despite demonstration of target engagement, without additional observed safety issues.

Keyphrases

multiple myeloma
open label
social media
acute lymphoblastic leukemia
double blind
acute myeloid leukemia
placebo controlled
clinical trial
randomized controlled trial
diffuse large b cell lymphoma